by Clinical Neuropsychologist | Thursday, September 12, 2024 | Dementia
Abstract INTRODUCTION Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer’s disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel...
by Clinical Neuropsychologist | Thursday, September 12, 2024 | Dementia
Abstract INTRODUCTION The molecular basis of cognitive resilience (CR) among pathologically confirmed Alzheimer’s disease (AD) cases is not well understood. METHODS Abundance of 13 cell types and neuronal subtypes in brain bulk RNA-seq data from the anterior...
by Clinical Neuropsychologist | Thursday, September 12, 2024 | Dementia
Abstract INTRODUCTION Regional glucose hypometabolism resulting in glutamate loss has been shown as one of the characteristics of Alzheimer’s disease (AD). Because the impact of AD varies between the sexes, we utilized glutamate-weighted chemical exchange...
by Clinical Neuropsychologist | Wednesday, September 11, 2024 | Dementia
Abstract INTRODUCTION We examined the relations of misfolded alpha synuclein (α-synuclein) with Alzheimer’s disease (AD) biomarkers in two large independent cohorts. METHODS We included Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably...
by Clinical Neuropsychologist | Wednesday, September 11, 2024 | Dementia
Abstract INTRODUCTION Word-list recall tests are routinely used for cognitive assessment, and process scoring may improve their accuracy. We examined whether Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog) derived, process-based digital...
